Insights+: Key Deals of JP Morgan Healthcare Conference 2021
Shots: The P-III APSEN study involve assessing of Brukinsa (zanubrutinib) vs AbbVie’s Imbruvica (ibrutinib) in 229 patients with r/r or TN WM across 61 centers in the US, EU and Australia The P-III APSEN study resulted in not meeting its 1EPs, i.e, superiority in CR & VGPR rate in up to 3yrs.; in r/r patients […]Read More